Schroder Investment Management Group Has $1.27 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Schroder Investment Management Group trimmed its position in shares of Laboratory Co. of America Holdings (NYSE:LH) by 24.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,554 shares of the medical research company’s stock after selling 1,810 shares during the period. Schroder Investment Management Group’s holdings in Laboratory Co. of America were worth $1,274,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Graney & King LLC acquired a new stake in shares of Laboratory Co. of America during the 4th quarter worth approximately $26,000. Fortitude Family Office LLC lifted its stake in Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 127 shares during the last quarter. Human Investing LLC bought a new position in shares of Laboratory Co. of America in the 4th quarter valued at $39,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Laboratory Co. of America during the 4th quarter worth $44,000. 95.94% of the stock is owned by institutional investors.

Laboratory Co. of America Stock Down 4.7 %

Shares of NYSE:LH opened at $222.49 on Monday. The business has a fifty day simple moving average of $243.63 and a 200 day simple moving average of $234.95. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The firm has a market cap of $18.62 billion, a P/E ratio of 25.23, a P/E/G ratio of 1.71 and a beta of 1.12. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Analyst Ratings Changes

Several analysts recently weighed in on LH shares. Jefferies Financial Group raised their price objective on Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Evercore ISI upgraded shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their price target for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Bank of America upped their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Morgan Stanley raised their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Finally, StockNews.com upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Sunday. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Laboratory Co. of America currently has a consensus rating of “Moderate Buy” and a consensus price target of $270.38.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, CMO Amy B. Summy sold 226 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $250.40, for a total transaction of $56,590.40. Following the transaction, the chief marketing officer now directly owns 4,544 shares in the company, valued at approximately $1,137,817.60. This represents a 4.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Adam H. Schechter sold 6,121 shares of Laboratory Co. of America stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the sale, the chief executive officer now owns 86,445 shares of the company’s stock, valued at $21,146,175.90. This represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,258 shares of company stock worth $3,753,177 over the last three months. 0.85% of the stock is owned by company insiders.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.